SR1375
Phase 2Small molecule
SR1375 is one of 45 small molecule programs targeting Efficacy and Safety. It is currently in Phase 2.
1
Indications
3
Total Trials
1
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
228 competitors in Efficacy and Safety
#DrugCompanyPhaseTrials
1Rinvoq
AbbViePhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Rapamune
PPrism Pharmaceuticals
Phase 3
Rilutek
AAzurity Pharmaceuticals
Phase 3
Kineret
SSwedish Orphan Biovitrum
Phase 3
UPLIZNA
HHorizon Therapeutics Ireland DAC
Phase 3
Becotatug Vedotin
FFudan University
Phase 3
Apatinib Mesylate
BBukwang Pharmaceutical
Phase 3
Raphamin
MMateria Medica Holding
Phase 3
Lerodalcibep
LLIB Therapeutics LLC
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Phase 11 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SR1375. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details